₹-64.50
(Market cap
₹1,65,359 Cr
Recently Viewed
Clear AllMarket cap
₹1,65,359 Cr
Revenue (TTM)
₹10,314 Cr
P/E Ratio
66.7
P/B Ratio
10.3
Div. Yield
0.5 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹2,479 Cr
ROE
15.4 %
ROCE
20.5 %
Industry P/E
36.2
EV/EBITDA
42.3
Debt to Equity
0
Book Value
₹602.6
EPS
₹95.5
Face value
2
Shares outstanding
265,468,580
CFO
₹14,366.06 Cr
EBITDA
₹22,110.62 Cr
Net Profit
₹16,352.23 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Divi's Lab
| -2.6 | 2.6 | -0.1 | 8.3 | 25.1 | 10.3 | 19.8 |
|
BSE Sensex
| -7.3 | 4.0 | -6.1 | 1.9 | 9.1 | 10.0 | 11.8 |
|
BSE Healthcare
| 0.1 | 2.8 | 1.5 | 5.2 | 24.0 | 13.6 | 10.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Divi's Lab
| 5.3 | 55.7 | 14.4 | -27.0 | 21.5 | 111.2 | 25.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Divi's Lab
|
6,229.0 | 1,65,359.1 | 10,314.0 | 2,479.0 | 28.5 | 16.7 | 66.7 | 10.3 |
| 373.2 | 3,405.7 | 2,521.8 | 202.5 | 9.6 | 14.3 | 16.8 | 2.3 | |
| 1,069.7 | 13,091.7 | 2,512.3 | 543.7 | 28.3 | 19.3 | 24.1 | 4.1 | |
| 422.7 | 7,335.0 | 1,053.1 | 293.6 | 32.3 | 24.6 | 25 | 5.7 | |
| 1,081.7 | 11,311.6 | 1,158.7 | 309.6 | 31.9 | 17.3 | 36.2 | 6.0 | |
| 1,672.1 | 31,666.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 36.4 | 6.4 | |
| 319.1 | 3,480.9 | 159.3 | 47.8 | 39.0 | 18.6 | 72.8 | 12.6 | |
| 15,295.0 | 19,631.9 | 1,575.1 | 179.1 | 14.9 | 11.4 | 109.6 | 11.8 | |
| 893.9 | 4,117.0 | 588.5 | 102.9 | 22.1 | 12.7 | 40.5 | 4.9 | |
| 196.1 | 5,166.3 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 7.8 |
3 min read•By Udhayaprakash
6 min read•By Kumar Shankar Roy
Premium pharma player: Divis Labs
1 min read•By Yash Rohra
How to spot current performers
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom... synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India. Read more
Incorporated
1990
Chairman
Ramesh BV Nimmagadda
Managing Director
Murali K Divi
Group
Divis Labs
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Divi's Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Divi's Laboratories Ltd is ₹6,229.00 (NSE) and ₹6,306.80 (BSE) as of 17-Apr-2026 IST. Divi's Laboratories Ltd has given a return of 25.07% in the last 3 years.
The P/E ratio of Divi's Laboratories Ltd is 66.70 times as on 17-Apr-2026, a 84 premium to its peers’ median range of 36.20 times.
The P/B ratio of Divi's Laboratories Ltd is 10.34 times as on 17-Apr-2026, a 352 premium to its peers’ median range of 2.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
69.83
|
10.22
|
|
2024
|
56.92
|
6.71
|
|
2023
|
41.05
|
5.87
|
|
2022
|
39.49
|
9.97
|
|
2021
|
48.56
|
10.37
|
The 52-week high and low of Divi's Laboratories Ltd are Rs 7,071.50 and Rs 5,596.00 as of 19-Apr-2026.
Divi's Laboratories Ltd has a market capitalisation of ₹ 1,65,359 Cr as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Divi's Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.